Supported by fresh research and backed by newly constructed, cutting edge manufacturing facilities, Immudyne is re-introducing European partners to the benefits of beta glucan at BIO-Europe Spring® 2010.
Meetings in Barcelona with pharmaceuticals and biotechs represent the first business development effort outside Japan for Chiome Bioscience, which recently established a successful record for generating antibodies with unique function against multiple-trans-membrane proteins through a proprietary in vitro platform called the ADLib system.
Cevec Pharmaceuticals uniquely offers a single human cell line from original research all the way to market-scale production with CAP-T, a transient cell line for rapid protein expression in drug discovery and development as a complement to the Cevec amniocyte high yield production (CAP) technology.
Oncolix thinks its first-in-class drug Prolanta has the makings to become a blockbuster drug for breast cancer therapy.
One week ahead of BIO-Europe 2009, Medgenics announced its first preclinical development and option agreement with what it described as “a major international biopharmaceutical company that is a market leader in the field of hemophilia.” Read more »
In a recent report to the Board, the CEO of Pacific Biometrics (PBI), Ron Helm, reported a second trend driving growth is the fast turnaround work the company performs developing assays for a growing scope of biomarkers, which favors “smaller labs, like PBI, that are nimble and flexible, and plays into our biomarker development strength.” Read more »
At BIO-Europe 2009, Compendia Bioscience is searching for 10 to 20 potential partners for the risk-sharing program to identify a precisely targeted patient population for a partner’s innovative cancer therapeutic, in exchange for future milestone and/or royalty payments for the successful drug. Read more »
“Success in biotechnology is tightly linked to achieving milestones critical to funding, and the second concern is protection of intellectual property,” said Detlef Behrens of Piramal Healthcare. “We have a long and deep track record both formulation and for IP protection,” he said, “It is something I look forward to discussing with potential partners at BIO-Europe in Vienna.” Read more »
Newsletter